Clinical Trials

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07200947 2025-10-01

QL1706

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

278 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Phase 4 Not yet recruiting

762 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

76 enrolled

Phase 4 Not yet recruiting

NSCLC

NCT06931145 2025-04-23

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

50 enrolled

Small Cell Lung Carcinoma

NCT06890182 2025-03-21

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

31 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

288 enrolled

Advanced Non-small Cell Lung Cancer

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT06786312 2025-01-22

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

34 enrolled

Small Cell Lung Carcinoma

NCT06672068 2024-12-30

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

60 enrolled

NSCLC

NCT06732258 2024-12-27

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

12 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

430 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06688656 2024-11-14

Peri-E

Lung Neoplasms

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

350 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06604351 2024-09-19

Example

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Carcinoma, Non-Small-Cell Lung

NCT06497530 2024-07-12

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Small Cell Lung Carcinoma

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

178 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Non-small Cell Lung Cancer Metastatic

NCT06391008 2024-04-30

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

44 enrolled

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

NCT06375109 2024-04-19

NeoSCLC-001

60 enrolled

Phase 2/3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

401 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT06306560 2024-03-12

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

40 enrolled

Small Cell Lung Carcinoma

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

BreastGynecologicHead & NeckThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

642 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

58 enrolled